Chun-Nun Chao^1,2, Chiung-Yao Fang^2,3, Chia-Hsin Hou¹, Jen-Tsung Yang^4,5, Yu-Ping Wu^4,6, Jui-Chieh Chen^6,*

Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.083962 - 13 August 2026

Abstract Objectives: Temozolomide (TMZ) resistance remains a major challenge in glioblastoma (GBM) treatment. This study investigated the role of miR-152-3p and its downstream target, transforming growth factor-α (TGF-α), in regulating TMZ sensitivity in GBM. Methods: Public GEO and CGGA datasets were analyzed to evaluate the expression and prognostic significance of miR-152-3p. TMZ-resistant GBM cell lines (U87MGR and DBTRG-05MGR) were established by continuous TMZ exposure. Gain- and loss-of-function experiments were performed using miR-152-3p mimics and inhibitors. Cell viability, apoptosis, and TGF-α expression were assessed by MTT, qRT-PCR, and Western blot analyses. Results: miR-152-3p expression was significantly decreased in recurrent… More >

Fang-Ying Chiu^1,2,3,*, Yun Yen^2,4,5,6

Oncology Research, Vol.34, No.6, 2026, DOI:10.32604/or.2026.077076 - 21 May 2026

Abstract Objective: Glioblastoma (GBM) is the most common primary malignant brain tumor and is characterized by significant intratumoral heterogeneity. This study aimed to investigate the clinical and genomic landscapes of GBM across diverse ethnic populations to identify potential prognostic markers. Methods: Leveraging The Cancer Imaging Archive (TCIA) and bioinformatics modeling, White, African, and Asian American cohorts were analyzed. Patients were stratified according to the 2021 WHO classification of central nervous system (CNS) tumors. Population-specific genomic drivers and phenotypic markers were evaluated for their impact on outcomes. Survival rates across age, sex, and ethnicity were estimated using the… More >

Pietro Tralongo^1,#,*, Mariagiovanna Ballato^1,#, Valeria Zuccalà², Vincenzo Fiorentino², Walter Giordano¹, Giovanna Casili³, Fabiola Bellinghieri⁴, Gerardo Caruso⁵, Filippo Flavio Angileri⁵, Guido Fadda², Maurizio Martini^2,§, Maria Caffo^5,§

Oncology Research, Vol.34, No.6, 2026, DOI:10.32604/or.2026.076088 - 21 May 2026

Abstract Glioblastoma (GB) is the most common primary malignant brain tumor of adulthood, and despite optimal safe resection and chemoradiation, it is still lethal. Neuroscience of cancer has shown that neuronal activities, as well as neurotransmitters, play an active role in the glioma microenvironment. This article aims to integrate the existing literature on the role of neurotransmitters and their receptors in glioblastoma, as well as other gliomas, highlighting areas of therapeutic intervention in the neuron-tumor interface. We will describe the neuro–glioma interface, including functional neuron–glioma synapses and activity-dependent tumor growth. We will also discuss major neurotransmitter… More > Graphic Abstract

Gerardo Ramírez-Mejía^1,#, Sofía Plata-Burgos^1,#, Raquel Cuevas-Díaz Duran², Adrian Ledesma-Beiza¹, Cynthia Sámano¹, Thalía Estefanía Sánchez-Correa³, Ernesto Soto-Reyes^1,*

BIOCELL, Vol.50, No.3, 2026, DOI:10.32604/biocell.2026.075061 - 23 March 2026

Abstract Objectives: Glioblastoma multiforme (GBM) is a highly aggressive brain tumor characterized by extensive transcriptional and epigenetic dysregulation. Brother of the Regulator of Imprinted Sites (BORIS/CTCFL) has been implicated in oncogenic transcriptional programs in several cancers, but its role in GBM remains poorly defined. This study aimed to characterize BORIS-associated transcriptional programs in GBM and to assess their functional relevance using integrative computational and experimental approaches. Methods: Transcriptomic data from The Cancer Genome Atlas (TCGA)-GBM and Genotype-Tissue Expression (GTex) brain cortex were analyzed following batch correction, differential expression analysis, and gene ontology enrichment. TCGA-GBM samples were… More >

Saad Alobid^1,#, Hussam Albassam^1,#, Tebyan O. Mirgany², Faris Almutairi¹, Mohammed Mufadhe Alanazi¹, Ahmed H. Bakheit², Hanadi H. Asiri², Eram Eltahir³, Gamaleldin I. Harisa^3,*

Oncology Research, Vol.34, No.4, 2026, DOI:10.32604/or.2025.073371 - 23 March 2026

Abstract Objective: Glioblastoma (GB) therapy is challenged by tumor heterogeneity and multidrug resistance (MDR), highlighting the need for effective therapies. This study aimed to explore the combined anticancer effects of Sunitinib (SNB) and Fenofibrate (FEN) on U87 cells. Methods: U87 cells were exposed to SNB, FEN, or their combination for 24 h, followed by evaluations of cell viability, migration, and clonogenic survival using MTT, scratch, and colony formation assays. Intracellular reactive oxygen species (ROS) were quantified via the 2^′, 7^′-dichlorofluorescein assay, while mitochondrial membrane potential (MMP) was assessed using JC-1 red/green fluorescence. Molecular docking was performed to… More > Graphic Abstract

Egor A. Turovsky^*, Elena G. Varlamova

BIOCELL, Vol.50, No.2, 2026, DOI:10.32604/biocell.2025.073728 - 14 February 2026

Abstract Objectives: Glioblastoma multiforme (GBM) is highly resistant to apoptosis. This study investigates the role of Selenoprotein M (SELENOM), a redox-regulating protein, in the response of human glioblastoma A-172 cells to staurosporine (STS) and hyperthermia. Methods: A stable SELENOM-knockdown (SELENOM-KD) cell line was created. We measured reactive oxygen species (ROS), mitochondrial membrane potential (ΔΨm), cell death, and apoptotic gene expression. Results: SELENOM-KD increased basal ROS levels and induced mitochondrial dysfunction. It sensitized cells to STS-induced apoptosis, enhancing the upregulation of pro-apoptotic genes. Conversely, under hyperthermia (42°C), SELENOM-KD cells exhibited significant thermoresistance, with 52% survival vs. 99% death More > Graphic Abstract

Wei-Ting Hsueh^1,#, Kwang-Yu Chang^1,2,3,#, Chin-Chuan Tsai^4,5, Kuan-Tso Chen^5,6, Kuen-Jang Tsai⁷, Zi-Xuan Hong⁸, Chan-Chuan Liu², Jui-Mei Chu², Li-Ying Qiu², Yu-Yan Lan⁸, Chia-Hung Chien^8,*

Oncology Research, Vol.34, No.2, 2026, DOI:10.32604/or.2025.071258 - 19 January 2026

Abstract Objectives: Glioblastoma (GBM) is a prevalent malignant brain tumor prone to drug resistance. We previously found a strong correlation between SH3 domain GRB2-like endophilin B1 (SH3GLB1) and superoxide dismutase 2 (SOD2), which converts O₂ to hydrogen peroxide (H₂O₂). Prior studies show that H₂O₂ redox signaling is vital for physiological processes and can drive tumor progression. Therefore, we aim to define how H₂O₂ signaling regulates SH3GLB1 and AKT (protein kinase B) pathways in GBM and to assess whether modulating H₂O₂ reverses temozolomide (TMZ) resistance. Methods: We used cultured cells and pharmacological inhibitors and activators to confirm the significance of… More > Graphic Abstract

Kun Deng^1,2,3, Jianliang Huang^1,2,3, Danyang Li^2,3, Wei Gao^2,3, Minghua Wu^2,3,4,*, Mingsheng Lei^1,5,*

Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.069442 - 30 December 2025

Abstract Background: Glioblastoma (GBM) prognosis has seen little improvement over the past two decades. While immunotherapy has revolutionized cancer treatment, its impact on GBM remains limited. To characterize the evolving research landscape and identify future directions in GBM immunotherapy, we conducted a comprehensive bibliometric review. Methods: All literature related to immunotherapy in GBM from 1999 to 2024 was collected from the Web of Science Core Collection. CtieSpace and VOSviewer were used to conduct bibliometric analysis and visualize the data. Results: Bibliometric analysis identified 5038 publications authored by 23,335 researchers from 4699 institutions across 96 countries/regions, published in… More >

Enrique Oropeza-Maetínez¹, Eva G. Palacios-Serrato¹, Marina Macías-Silva², Angeles C. Tecalco-Cruz^1,*

European Cytokine Network, Vol.36, No.3, pp. 38-51, 2025, DOI:10.1684/ecn.2025.0503 - 28 February 2026

Abstract Background: Glioblastoma is a lethal primary brain tumor that is therapeutically challenging due to its rapid progression. Interferon-gamma (IFN-γ) signaling is altered in glioblastoma. Moreover, proteolytic enzymes, known as proteases, have been linked to the invasive growth of cancerous cells. In this study, we aimed to identify a glioblastoma-associated protease group and to determine its potential connection with IFN-γ signaling. Methods: Using cancer expression databases, we analyzed the differential expression of 35 proteases in glioblastoma and healthy brain tissue, and the relevance of their deregulation to patient survival. We also explored correlations between IFN-γ signaling… More >

Rym Akrout¹, Ludovic Leloup², Khouloud Ayed¹, Fabrice Parat², Sami Zekri^3,4, Wassim Y. Almawi¹, Rahma Boughriba¹, Hanen Attia¹, Olfa Masmoudi-Kouki⁴, Hervé Kovacic^2,*, Asma Gati^1,*

Oncology Research, Vol.33, No.12, pp. 3887-3906, 2025, DOI:10.32604/or.2025.070729 - 27 November 2025

Abstract Objectives: Cisplatin (CDDP) therapy for glioblastoma (GBM) is linked with several limitations, which include poor penetration of the blood-brain barrier (BBB), systemic toxicity, and the development of drug resistance mechanisms implicating oxidative stress dysregulation and compromised apoptotic pathways. This study evaluates C-Phycocyanin (C-PC) as a potential adjuvant to enhance CDDP efficacy by modulating redox balance and apoptosis. Methods: GBM cells (U87 and U87-EGFRvIII) were treated with CDDP, C-PC, or their combination. Cell viability was assessed by MTT assay; apoptosis was evaluated by DAPI staining and Western blot analysis of cleaved Caspase-3 and poly (ADP-ribose) polymerase… More > Graphic Abstract